HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

about

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

Item

http://www.wikidata.org/entity/Q47965547

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@en

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@nl

type

Item

label

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@en

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@nl

prefLabel

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@en

HER2 intratumoral heterogeneit ...... ER2-positive breast carcinoma.

@nl

P1476

HER2 intratumoral heterogeneit ...... HER2-positive breast carcinoma

@en

P2093

Anil V Parwani

http://www.w3.org/2001/XMLSchema#string

Bryce Portier

http://www.w3.org/2001/XMLSchema#string

Hiroaki Nitta

http://www.w3.org/2001/XMLSchema#string

Lai Wei

http://www.w3.org/2001/XMLSchema#string

Peter M Banks

http://www.w3.org/2001/XMLSchema#string

Yanjun Hou

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

P2888

s10549-017-4453-8

P304

447-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4453-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

Zaibo Li

P577

2017-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28799059

http://www.w3.org/2001/XMLSchema#string